Literature DB >> 8761362

Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel.

S Withoff1, W N Keith, A J Knol, J C Coutts, S F Hoare, N H Mulder, E G de Vries.   

Abstract

A panel of doxorubicin-resistant sublines of the human small-cell lung carcinoma cell line GLC4 displays decreasing DNA topoisomerase II alpha (TopoII alpha) mRNA levels with increasing resistance. In the present study we describe how this decrease may be regulated. No significant differences in TopoII alpha mRNA stability or gene arrangement were found, using mRNA slot-blotting and Southern blotting, in the most resistant cell line compared with the parental cell line. To investigate if TopoII alpha gene copy loss contributed to the mRNA decrease, fluorescence in situ hybridisation using a TopoII alpha-specific probe was performed. During doxorubicin resistance development, the composition of the population in each cell line shifted with increasing resistance, from a population in which most cells contain three TopoII alpha gene copies (GLC4) to a population in which most cells contain only two copies. A partial revertant of the most resistant cell line displayed a shift back to the original situation. We conclude that the TopoII alpha gene copy number decrease per cell line is in good agreement with the decreased TopoII alpha mRNA and protein levels, and TopoII activity levels in these cell lines which were described previously.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8761362      PMCID: PMC2074676          DOI: 10.1038/bjc.1996.393

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  36 in total

1.  Growth state- and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase.

Authors:  K Kimura; M Saijo; M Ui; T Enomoto
Journal:  J Biol Chem       Date:  1994-01-14       Impact factor: 5.157

2.  Discrete localization of different DNA topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions.

Authors:  N Zini; S Santi; A Ognibene; A Bavelloni; L M Neri; A Valmori; E Mariani; C Negri; G C Astaldi-Ricotti; N M Maraldi
Journal:  Exp Cell Res       Date:  1994-02       Impact factor: 3.905

Review 3.  Drug resistance associated with altered DNA topoisomerase II.

Authors:  W T Beck; M K Danks; J S Wolverton; R Kim; M Chen
Journal:  Adv Enzyme Regul       Date:  1993

Review 4.  Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors.

Authors:  Y Pommier; F Leteurtre; M R Fesen; A Fujimori; R Bertrand; E Solary; G Kohlhagen; K W Kohn
Journal:  Cancer Invest       Date:  1994       Impact factor: 2.176

5.  Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20.

Authors:  W N Keith; F Douglas; G C Wishart; H M McCallum; W D George; S B Kaye; R Brown
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

6.  Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy.

Authors:  I Husain; J L Mohler; H F Seigler; J M Besterman
Journal:  Cancer Res       Date:  1994-01-15       Impact factor: 12.701

7.  Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay.

Authors:  S Withoff; E F Smit; G J Meersma; A van den Berg; H Timmer-Bosscha; K Kok; P E Postmus; N H Mulder; E G de Vries; C H Buys
Journal:  Lab Invest       Date:  1994-07       Impact factor: 5.662

8.  Altered gene expression in human leukemia K562 cells selected for resistance to etoposide.

Authors:  M K Ritke; J C Yalowich
Journal:  Biochem Pharmacol       Date:  1993-12-03       Impact factor: 5.858

9.  Intratumoral heterogeneity for amplified genes in human breast carcinoma.

Authors:  U Lönn; S Lönn; B Nilsson; B Stenkvist
Journal:  Int J Cancer       Date:  1994-07-01       Impact factor: 7.396

Review 10.  Translocation (3;21)(q26;q22) in therapy-related myelodysplasia following drugs targeting DNA-topoisomerase II combined with alkylating agents, and in myeloproliferative disorders undergoing spontaneous leukemic transformation.

Authors:  J Pedersen-Bjergaard; B Johansson; P Philip
Journal:  Cancer Genet Cytogenet       Date:  1994-08
View more
  16 in total

1.  High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy.

Authors:  Yong Won Choi; Mi Sun Ahn; Jin-Hyuk Choi; Hyun Woo Lee; Seok Yun Kang; Seong Hyun Jeong; Joon Seong Park; Jae Ho Han; Jang-Hee Kim; Seung Soo Sheen
Journal:  Int J Hematol       Date:  2015-11-19       Impact factor: 2.490

2.  Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.

Authors:  Michael F Press; Guido Sauter; Marc Buyse; Leslie Bernstein; Roberta Guzman; Angela Santiago; Ivonne E Villalobos; Wolfgang Eiermann; Tadeusz Pienkowski; Miguel Martin; Nicholas Robert; John Crown; Valerie Bee; Henry Taupin; Kerry J Flom; Isabelle Tabah-Fisch; Giovanni Pauletti; Mary-Ann Lindsay; Alessandro Riva; Dennis J Slamon
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

3.  Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.

Authors:  T A Järvinen; M Tanner; V Rantanen; M Bärlund; A Borg; S Grénman; J Isola
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

4.  Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor.

Authors:  A Arivazhagan; Durairaj Mohan Kumar; Vinay Sagar; Irene Rosita Pia Patric; S Sridevi; Balaram Thota; Mallavarapu R Srividya; K Prasanna; K Thennarasu; Neelima Mondal; A S Hegde; B A Chandramouli; V Santosh; M R S Rao; P Kondaiah; K Somasundaram
Journal:  J Neurooncol       Date:  2011-11-19       Impact factor: 4.130

Review 5.  HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics.

Authors:  Beyhan Ataseven; Daniela Gologan; Angela Gunesch; Victoria Kehl; Bernhard Hoegel; Michaela Beer; Wolfgang Eiermann
Journal:  Breast Care (Basel)       Date:  2012-12       Impact factor: 2.860

Review 6.  Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.

Authors:  Atocha Romero; Miguel Martín; Maggie C U Cheang; José Antonio López García-Asenjo; Belén Oliva; Xiaping He; Miguel de la Hoya; Jose Ángel García Sáenz; Manuel Arroyo Fernández; Eduardo Díaz Rubio; Charles M Perou; Trinidad Caldés Llopis
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

7.  PROGNOSTIC VALUE OF TOPOISOMERASE 2-ALPHA AND B-MYB IN EARLY BREAST CANCER TREATED WITH ADJUVANT CHEMOTHERAPY.

Authors:  Ljubica Radmilović Varga; Natalija Dedić Plavetić; Paula Podolski; Davor Mijatović; Ana Kulić; Damir Vrbanec
Journal:  Acta Clin Croat       Date:  2021-03       Impact factor: 0.780

8.  Topoisomerase IIalpha in Wilms' tumour: gene alterations and immunoexpression.

Authors:  M Tretiakova; M Turkyilmaz; T Grushko; M Kocherginsky; C Rubin; B Teh; X J Yang
Journal:  J Clin Pathol       Date:  2006-03-23       Impact factor: 3.411

Review 9.  Polymeric Nanocarriers: A Transformation in Doxorubicin Therapies.

Authors:  Kamila Butowska; Anna Woziwodzka; Agnieszka Borowik; Jacek Piosik
Journal:  Materials (Basel)       Date:  2021-04-22       Impact factor: 3.623

10.  Use of a rapid throughput in vivo screen to investigate inhibitors of eukaryotic topoisomerase II enzymes.

Authors:  T R Hammonds; A Maxwell; J R Jenkins
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.